Martin Murphy is chief executive officer of Syncona Ltd, which is focused on investing in and building global leaders in life science. The company takes a ‘long-term view’, explains Murphy, and this is demonstrated by a significant ownership stake in its portfolio companies. Syncona is expert in investing in established leaders in the field of genetic medicine, particularly gene and cell therapy. ‘We’re building the next generation of healthcare companies, and we underpin them with a deep pool of capital. We’re aiming to deliver dramatic efficacy in areas of high unmet medical need.’ The investment team at Syncona all have strong scientific backgrounds with significant commercial experience.